These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37548904)

  • 21. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.
    Mofid S; Bolislis WR; Kühler TC
    Clin Ther; 2022 Feb; 44(2):306-322. PubMed ID: 35074209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases.
    Alipour-Haris G; Liu X; Acha V; Winterstein AG; Burcu M
    Clin Transl Sci; 2024 Aug; 17(8):e13903. PubMed ID: 39092896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The application of real-world evidence in drug regulatory decision-making].
    Wicherski J; Haenisch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
    Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
    Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.
    Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL
    Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.
    Gressler LE; Marinac-Dabic D; Resnic FS; Williams S; Yang K; Weichold F; Avila-Tang E; Mack C; Coplan P; Panagiotou OA; Pappas G
    Ther Innov Regul Sci; 2024 Nov; 58(6):1042-1052. PubMed ID: 39060838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications.
    Chang LC; Mahmood R; Qureshi S; Breder CD
    PLoS One; 2017; 12(6):e0178104. PubMed ID: 28570569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    Clin Pharmacol Ther; 2022 Jan; 111(1):310-320. PubMed ID: 34689334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.
    Oehrlein EM; Graff JS; Harris J; Perfetto EM
    Patient; 2019 Aug; 12(4):375-381. PubMed ID: 30666526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions.
    Li P; Wang S; Chen Y
    Ther Innov Regul Sci; 2023 Nov; 57(6):1167-1179. PubMed ID: 37624556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union.
    Zou KH; Berger ML
    Bioengineering (Basel); 2024 Aug; 11(8):. PubMed ID: 39199742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
    Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
    JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?
    Flynn R; Plueschke K; Quinten C; Strassmann V; Duijnhoven RG; Gordillo-Marañon M; Rueckbeil M; Cohet C; Kurz X
    Clin Pharmacol Ther; 2022 Jan; 111(1):90-97. PubMed ID: 34689339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe.
    Davenport C; Gravel P; Wang Y; Williams SA; Wieland A; Mitlak B
    Ther Innov Regul Sci; 2024 May; 58(3):505-518. PubMed ID: 38341388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.